TERF1 and BRAF

Number of citations of the paper that reports this interaction (PubMedID 20936779)
85

Data Source:
BioGRID (two hybrid)

		TERF1	BRAF
Description		telomeric repeat binding factor 1	B-Raf proto-oncogene, serine/threonine kinase
Image
GO Annotations	Cellular Component	Nuclear Telomere Cap Complex Nuclear Chromosome, Telomeric Region Fibrillar Center Cell Nucleus Nucleoplasm Nucleolus Cytoplasm Spindle Nuclear Body Shelterin Complex	Nucleus Mitochondrion Cytosol Plasma Membrane Intracellular Membrane-bounded Organelle
	Molecular Function	DNA-binding Transcription Factor Activity, RNA Polymerase II-specific DNA Binding Double-stranded Telomeric DNA Binding Telomerase Activity Protein Binding Microtubule Binding DNA Binding, Bending Telomeric DNA Binding Identical Protein Binding Protein Homodimerization Activity Ankyrin Repeat Binding G-rich Strand Telomeric DNA Binding	Protein Kinase Activity Protein Serine/threonine Kinase Activity Calcium Ion Binding Protein Binding ATP Binding Small GTPase Binding Identical Protein Binding
	Biological Process	Telomere Maintenance Regulation Of Transcription By RNA Polymerase II Telomere Maintenance Via Telomerase Negative Regulation Of DNA Replication Telomere Capping Negative Regulation Of Telomere Maintenance Via Telomerase Negative Regulation Of Telomere Maintenance Via Semi-conservative Replication Response To Drug Meiotic Telomere Clustering Cell Division Negative Regulation Of Telomerase Activity Telomeric D-loop Disassembly T-circle Formation Negative Regulation Of Telomere Maintenance Via Telomere Lengthening Positive Regulation Of Shelterin Complex Assembly Negative Regulation Of Establishment Of Protein Localization To Telomere Negative Regulation Of Establishment Of RNA Localization To Telomere Negative Regulation Of Establishment Of Protein-containing Complex Localization To Telomere Negative Regulation Of Exonuclease Activity Negative Regulation Of Telomeric D-loop Disassembly	MAPK Cascade Activation Of MAPKK Activity Protein Phosphorylation Animal Organ Morphogenesis Positive Regulation Of Gene Expression Positive Regulation Of Glucose Transmembrane Transport Positive Regulation Of Peptidyl-serine Phosphorylation Negative Regulation Of Apoptotic Process Positive Regulation Of ERK1 And ERK2 Cascade Trehalose Metabolism In Response To Stress Cellular Response To Calcium Ion Establishment Of Protein Localization To Membrane
Pathways		Recognition and association of DNA glycosylase with site containing an affected pyrimidine Cleavage of the damaged pyrimidine Recognition and association of DNA glycosylase with site containing an affected purine Recognition and association of DNA glycosylase with site containing an affected purine Cleavage of the damaged purine Cleavage of the damaged purine Meiotic synapsis Packaging Of Telomere Ends Telomere Extension By Telomerase DNA Damage/Telomere Stress Induced Senescence	Spry regulation of FGF signaling Frs2-mediated activation Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants
Drugs			Sorafenib XL281 N-{3-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime Vemurafenib Regorafenib Dabrafenib
Diseases			Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Thyroid cancer Malignant melanoma
GWAS		Crohn's disease ( 22412388) Leukocyte telomere length ( 31171785)	anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy) ( 31835028) Bipolar disorder ( 31043756) Cerebrospinal fluid t-tau:AB1-42 ratio ( 26252872) Cerebrospinal T-tau levels ( 26252872) Mild influenza (H1N1) infection ( 26379185) Response to Vitamin E supplementation ( 22437554) Type 2 diabetes ( 28869590)
Interacting Genes		204 interacting genes: ACAT2 ACOT7 ACY1 AFAP1L2 AHCY AK1 AKR1A1 ALDOA AMPD2 AMPH ANXA2 ANXA5 ANXA8L1 APEX1 ARHGDIA ARPP21 ASS1 ATM BCL7B BIN2 BLM BRAF C12orf43 C1orf35 CALD1 CAPNS1 CASP7 CCDC9 CDC6 CEP85 CFL1 CKB CORO1B CPNE3 CRYBB1 CRYM DBN1 DBNL DCX DDX19B DDX21 DDX23 DDX24 DDX39A DLG5 DNAJB1 DNPH1 DPP3 DPYSL3 EEF1D EIF4B ENO2 EPB41L1 EPHX2 EVL FANCD2 FBP1 FBXO4 FEN1 FES FKBP8 GAMT GAPDH GIT1 GNL3L GNMT GSS H1-1 HCLS1 HDGFL2 HEXIM1 HEXIM2 HGD HMGN3 HMGN4 HMOX1 HNMT HOXA3 HSP90AB1 HSPA6 IPO5 JSRP1 KDM1A KEAP1 KIFBP KLHDC4 KPNB1 LASP1 LDHA LDHB LRSAM1 LYAR MAP4 MAP7 MAPK12 MAPRE1 MCM2 MDH1 MSN MT1X MVK NAP1L1 NBN NEFL NEK7 NME1 NME2 NOL12 NOL3 NUDCD2 NUDT14 NUMA1 NXNL1 OCM2 OGFR PA2G4 PACSIN2 PAFAH1B3 PAGE2 PAICS PAK4 PCP4 PEPD PFKP PFN2 PGD PGLS PGM1 PGM2 PINX1 PKM PNMT POT1 PPM1G PRDX1 PRDX6 PRKCB PTMA PTPN5 RBMY1A1 RECQL4 RIC8A RLIM RNF10 RPAP3 RPL19 RTN3 RTN4 SALL1 SARS1 SBDS SENP8 SET SH3BP1 SH3GL2 SH3GL3 SHFL SIRPD SKP1 SMAD9 SMARCC2 SNCG SOAT1 SP100 SRM SRSF6 STUB1 SULT1C2 SUPT5H SYK TALDO1 TBC1D10A TBCD TBL1X TCIRG1 TERT THG1L TINAG TINF2 TKT TMSB10 TMSB4Y TNKS TNKS2 TNPO2 TOMM34 TPI1 TRIM16 TRIP10 TRMT1 TUBB2A TUBB3 TUBB4B UBE2M UTP14A WARS1 WDR4 WFS1 YWHAG ZBTB16 ZC3H18 ZFP36L1 ZHX1 ZNF790	39 interacting genes: AKT1 ARAF AURKA BAD CCDC88A HRAS ITCH KRAS LATS2 MAP2K1 MAP2K2 MAP2K3 MAP2K6 MAPK1 MRAS NANOG OIP5 PAK2 PPP2CA PPP2R2A PRKACA PRKCE RAF1 RAP1A RAP1GAP RASSF1 RHEB SFN SGK1 SPRY2 STK11 TERF1 TERT UBE2L3 YWHAB YWHAG YWHAH YWHAQ YWHAZ
Entrez ID		7013	673
HPRD ID		02975	01264
Ensembl ID		ENSG00000147601	ENSG00000157764
Uniprot IDs		P54274	A0A2R8Y8E0 P15056
PDB IDs		1BA5 1H6O 1ITY 1IV6 1W0T 3BQO 3L82 5HKP 5WIR 5XUP	1UWH 1UWJ 2FB8 2L05 3C4C 3D4Q 3IDP 3II5 3NY5 3OG7 3PPJ 3PPK 3PRF 3PRI 3PSB 3PSD 3Q4C 3Q96 3SKC 3TV4 3TV6 4CQE 4DBN 4E26 4E4X 4EHE 4EHG 4FC0 4FK3 4G9C 4G9R 4H58 4JVG 4KSP 4KSQ 4MBJ 4MNE 4MNF 4PP7 4R5Y 4RZV 4RZW 4WO5 4XV1 4XV2 4XV3 4XV9 4YHT 5C9C 5CSW 5CSX 5CT7 5FD2 5HI2 5HID 5HIE 5ITA 5J17 5J18 5J2R 5JRQ 5JSM 5JT2 5VAL 5VAM 5VR3 5VYK 6B8U 6CAD 6N0P 6N0Q 6NSQ 6NYB 6PP9 6Q0J 6Q0K 6Q0T 6U2G 6U2H 6UAN
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?